
BioCam is a medical technology company that designs and manufactures a non-invasive endoscopic capsule for imaging the entire gastrointestinal tract. Their product suite includes the BioCam endoscopic capsule, an AI-powered telemedicine platform for automatic detection and real-time analysis of potential gastrointestinal threats, and a mobile application to assist patients with examination preparation. The company leverages advanced AI algorithms with up to 97% accuracy in lesion detection and enhances image resolution by up to 400%. BioCam aims to provide a patient-friendly, remote, and cost-effective alternative to traditional endoscopy methods, enabling real-time monitoring by physicians and improving diagnostic efficiency. The company has received multiple awards and recognitions, indicating strong market traction and innovation leadership in the health tech sector.

BioCam is a medical technology company that designs and manufactures a non-invasive endoscopic capsule for imaging the entire gastrointestinal tract. Their product suite includes the BioCam endoscopic capsule, an AI-powered telemedicine platform for automatic detection and real-time analysis of potential gastrointestinal threats, and a mobile application to assist patients with examination preparation. The company leverages advanced AI algorithms with up to 97% accuracy in lesion detection and enhances image resolution by up to 400%. BioCam aims to provide a patient-friendly, remote, and cost-effective alternative to traditional endoscopy methods, enabling real-time monitoring by physicians and improving diagnostic efficiency. The company has received multiple awards and recognitions, indicating strong market traction and innovation leadership in the health tech sector.
What they make: A pill-sized endoscopic capsule plus AI-powered telemedicine platform and patient mobile app for non-invasive GI imaging
Founded / HQ: Founded 2020; Wrocław, Poland
Tech / performance claims: AI lesion detection accuracy reported up to 97%; image resolution improvement reported up to 400%
Team size: ~34 employees (public profile figure)
Funding: Total reported funding ~3,956,086 USD; multiple rounds with Seed noted as latest (2023)
Gastrointestinal imaging and diagnostics—non-invasive capsule endoscopy and automated lesion/pathology detection.
2020
Biotechnology
Latest seed round reported on public profiles
3956086 USD
Total funding amount and last funding date reported on public profile snapshot
“Multiple investors including Level2 Ventures, Dawid Ubran/Urban, LT Capital, National Centre for Research and Development and supporters from EU funding programs”